OP15 Multi-omic data integration with network analysis reveals underlying molecular mechanisms driving Crohn’s disease heterogeneity
ECCO'20 Vienna
2020
OP16 Influence of early life factors on the development of intestinal microbiota of infants born to mothers with and without IBD
ECCO'20 Vienna
2020
OP17 Protein intakes and risk of inflammatory bowel disease in the European Prospective Investigation into Cancer and Nutrition cohort (EPIC-IBD)
ECCO'20 Vienna
2020
OP18 Surgical prevention of anastomotic recurrence by excluding mesentery in Crohn’s disease: The SuPREMe-CD study
ECCO'20 Vienna
2020
OP19 Perinatal factors do not affect paediatric inflammatory bowel disease risk: A Scottish Nationwide Cohort study using administrative health data 1981–2017
ECCO'20 Vienna
2020
OP22 Crohn’s disease exclusion diet reduces bacterial dysbiosis towards healthy controls in paediatric Crohn’s disease
ECCO'20 Vienna
2020
OP23 Efficacy and safety of vedolizumab SC in patients with moderately to severely active Crohn’s disease: Results of the VISIBLE 2 study
ECCO'20 Vienna
2020
OP27 Long-term safety and efficacy of risankizumab treatment in patients with Crohn’s disease: Final results from the Phase 2 open-label extension study
ECCO'20 Vienna
2020
OP28 Gene expression (GE) values in a phase 2 trial of mirikizumab in ulcerative colitis (UC) correlate better with histopathology (HP) than endoscopy (EN) and Mayo scores
ECCO'20 Vienna
2020
OP30 The interplay of microbiome dysbiosis and immune system deregulation in patients with Crohn’s disease
ECCO'20 Vienna
2020
OP31 Meta–omics reveals microbiome-driven proteolysis as a contributing factor to the severity of ulcerative colitis disease activity
ECCO'20 Vienna
2020
OP32 Mincle signalling promotes intestinal mucosal inflammation through induction of macrophage pyroptosis and neutrophil chemotaxis in Crohn’s disease
ECCO'20 Vienna
2020